Based on studies that have revealed how specific malignancies thrive on cholesterol, and that raised serum cholesterol levels are linked to the risk of cancer and a drug compound called leelamine that has shown to retard tumor-growth in melanoma...
Endomag received premarket approval from the FDA for Magtrace, the novel non-radioactive dual-tracer for lymphatic plotting in breast cancer patients which facilitates the implementation of magnetic detection during sentinel lymph node biopsy procedures to spot sentinel lymph nodes for surgical excision.
Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences conducted an international mutual study which discovered a novel blood test that can foresee advanced prostate cancer patient response to particular treatments, resulting in better survival.
At the beginning of this month, the U.S. Food and Drug Administration (FDA) announced to withdraw drugs containing valsartan, which treat high blood pressure and heart failure. The drugs were withdrawn due to the presence of N-nitrosodimethylamine (NDMA), which might lead to cancer.
The Newton Massachusetts-based company, Karyopharm Therapeutics, who developed a new class of drugs to treat multiple myeloma, is in the process of submitting a new drug application to the FDA for their selinexor drug.
In a major breakthrough in cancer research, a team of scientists from the University of Toronto, The Institute of Cancer Research, London, The Netherlands Cancer Institute and the University of Bern have discovered how cells repair damaged strands of DNA. They revealed a brand new protein complex in cells that protect broken DNA ends and causes its repair, in their study published in Nature on Wednesday.
Stanford University School of Medicine Researchers have developed a magnetic wire that catches tumor cells flowing in the bloodstream. The wire, inserted into a vein, captures even limited tumor cells, ushering in a new means to detect cancer early.
University of Adelaide researchers have designed a new molecule which targets a protein essential to the growth of most cancers. The protein target is called proliferating cell nuclear antigen (PCNA), also known as the human sliding clamp.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.